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Introduction: Benefits of disease-modifying anti-rheumatic drugs (DMARD) in early rheumatoid arthritis
patients (ERAP) will be achieved if patients follow prescribed treatment. Objective was to investigate whether timing
of first non-persistence period and/or duration of persistence during the first 4 years of follow-up predicted disease
outcomes at the 5th year in a cohort of ERAP, initiated in 2004.
Patients and Methods: Up to February 2015, charts of 107 ERAP with at least 5 years of follow-up and prospective
6-month assessments of disease activity, disability and persistence were reviewed. Non-persistence was defined as
omission of DMARD and/or corticosteroids for at least 7 consecutive days; regarding methotrexate, one weekly
missing dose was considered non-persistence. Persistence was recorded through an interview (up to 2008) and
thereafter through a questionnaire; persistence duration was recorded in months of continuous medicationtaking. At
the 5th year, disease activity was defined according to Disease Activity Score (DAS)28, and disability according to Health
Assessment Questionnaire (HAQ). Descriptive statistics and linear and Cox regression analyses were used.
Results: At study entry, patients were more frequently middle-aged (39.1 ± 13.3 years) and female (88.8 %), as well as
more likely to have high disease activity and disability. Over the first 4 years of follow-up, 54.2 % of the patients had
indications for oral corticosteroids and all traditional DMARDs. Almost 70 % had at least one period of non-persistence,
and their follow-up (median, 25th–75th interquartile range) to first non-persistence period was 13 months (1–31).
Persistence duration during the first 4 years predicted subsequent DAS28 (in addition to gender and baseline DAS28)
and HAQ (in addition to age). During the 5th year, 68 patients (56 women) achieved sustained remission (DAS28 < 2.6).
In female population (n = 95), baseline DAS28 (odds ratio [OR], 0.65; 95 % confidence interval [CI], 0.50–0.83; p = 0.001)
and persistence duration (OR, 1.04; 95 % CI, 1–1.08; p = 0.05) were predictors. Also, 84 patients achieved sustained
function (HAQ <0.21), and baseline DAS28 and age were the only predictors. Timing of first non-persistence period did
not impact outcomes.
Conclusions: Persistence duration with DMARDs within the first 4 years of RA predicted subsequent favorable
outcomes in ERAP; additional predictors were younger age, male gender and lower disease activity at diagnosis.* Correspondence: virtichu@gmail.com
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The window of opportunity concept states that there are
superior clinical responses and the potential for remission
when patients with rheumatoid arthritis (RA) are man-
aged early and aggressively with disease-modifying anti-
rheumatic drugs (DMARDs) [1–3]. Early RA clinics are
the perfect setting to address such concept, as patients
with recent disease onset are referred to experts in rheu-
matologic care without delay. Nonetheless, it seems intui-
tive to assume that the full benefit of the pharmacologic
intervention will be achieved if patients follow prescribed
regimens reasonably closely.
Medication adherence refers to the patient’s act of con-
forming to the recommendations made by the health care
provider with respect to timing, dosage and frequency of
medication-taking [4, 5]. Medication adherence can be
divided into three major components: (1) persistence, de-
fined as the length of time a patient fills prescriptions
without permissible gaps; (2) initiation adherence, defined
as the patient starting with the intended treatment; and
(3) execution adherence that results from the comparison
between the prescribed drug regimen and the patient’s ac-
tual drug-taking behavior [4].
Poor adherence with therapy affects 20 to 70 % of
patients with RA, sometimes during their follow-up
[6–14]. Local experience within a cohort of Mexican
Mestizo patients with early RA (ERAP) confirmed these
data and additionally showed that poor adherence with
traditional DMARDs was associated with increased dis-
ease flares, decreased rates of remission and worse
patient-reported outcomes [15–17], although the mecha-
nisms were not examined. In particular, there may be as-
pects within the adherence and persistence constructs,
such as duration (of persistence) or timing (of first non-
persistence period), that may have a different (and/or
additive) impact on outcomes. We sought to explore
this hypothesis in a well-defined population of ERAPs
in whom persistence was prospectively evaluated and
the concept of window of opportunity was extended to
the construct of persistence.
The following were the specific objectives of the study:
1. To investigate if the timing of first non-persistence
period and/or duration of persistence during the first
4 years of follow-up were predictors of the level of
disease activity at the fifth year of follow-up and of
achieving sustained remission (SR).
2. If the first objective was achieved, we planned to
extend the analysis to a patient-reported outcome
and investigate a similar impact on patient function
as evaluated per the Health Assessment Questionnaire
(HAQ) [18].
3. To define additional predictors of disease
outcomes.Methods
Setting and study population
The Instituto Nacional de Ciencias Médicas y Nutrición
Salvador Zubirán is a national referral center for rheum-
atic diseases that belongs to the National Institutes of
Health in Mexico City. In 2004, an early arthritis clinic
was established. Patients entering the clinic had disease
durations of less than 1 year when first evaluated and no
specific rheumatic diagnosis other than RA. Patients
were evaluated every 2 months during the first 2 years
of follow-up and thereafter every 2, 4 or 6 months (fixed
for all the patients from the baseline evaluation), de-
pending on patient and disease characteristics. Treat-
ment was prescribed by the rheumatologist in charge of
the clinic and was given using a treat-to-target (T2T) ap-
proach. Briefly, at every medical encounter, the Disease
Activity Score in 28 joints (DAS28) was calculated and
the level of disease activity defined. If remission was
achieved, no major treatment modifications were made;
if not, treatment was intensified with the aim of achiev-
ing remission, which was defined as DAS28 less than
2.6. Traditional DMARDs were used in 99 % of our popu-
lation, with or without corticosteroids (around 50 % of
the patients). From the beginning of the clinic, patients’
medication behavior was prospectively assessed, initially
through a structured interview and starting in November
2008 by using an instrument locally designed, the Con-
cordance Questionnaire (CQ) formerly called the Compli-
ance Questionnaire, which evaluates both constructs:
adherence to and persistence with therapy [16].
Up to February 2015, 165 ERAPs had been evaluated,
of whom 107 had at least 5 years of follow-up (19 pa-
tients were lost to follow-up, and 2 additional patients
died). The 5 years of follow-up was deemed to be suffi-
cient to accomplish the objectives described.
Rheumatic evaluations
At study entry, a complete medical history and demographic
data, along with disease-specific autoantibodies, were re-
corded. Medical evaluations were standardized and included
swollen and tender joint counts, acute reactant-phase deter-
minations, patient- and physician- reported outcomes,
comorbidity established by record review and treatment
assessment (names, doses and schedules of all drugs taken
since last visit), along with the evaluation of persistence.
Persistence evaluation
From 2004 to 2008, persistence was assessed through an
interview conducted at every visit by the same rheumatolo-
gist. Patients were directed to report the names, doses and
schedules of DMARDs and corticosteroids they had taken
since last visit (fixed at 6 months apart), initially spontan-
eously and if necessary directly. Then, patients were asked
about any missing and/or incorrect medications, doses
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of missing medication was recorded. The rheumatologist
compared the last prescription and the actual treatment,
and, if inconsistencies were found, they were resolved. Data
were collected in standardized formats.
Since 2008, persistence (and adherence) was evaluated
through the CQ. The performance of the CQ has shown
high sensitivity and satisfactory specificity to detect per-
sistence [16]. CQ was fulfilled without help by 95 % of
the patients.
Definitions
Sustained remission was assessed at the fifth year of
follow-up and defined if DAS28 was below 2.6 at the
three consecutive evaluations within that year [19, 20].
The DAS28 at the fifth year of follow-up was calcu-
lated as the mean of individual DAS28 from visits per-
formed during the fifth year.
Patient function was also evaluated at the fifth year of
follow-up. A patient was considered to be without dis-
ability if the HAQ score was sustained at or below 0.20
at all consecutive evaluations within that year. In addition,
HAQ score at the fifth year was derived from the mean of
individual HAQs from visits during the fifth year.
According to the interview, non-persistence with medi-
cation was defined as omission of at least one DMARD
and/or corticosteroid for at least 7 consecutive days.
Regarding methotrexate, at least one missing weekly dose
was considered non-persistence. Treatment modifications
because of adverse events and/or indicated by a different
physician for any reason (e.g., insufficient response, preg-
nancy, schedule surgery) were not considered non-
persistence under the construct. According to the CQ, a
patient was considered to be non-persistent if, in item 10
(“In the past 6 months, how often did you completely stop
taking your DMARDs?”), boxes 2 (“Sometimes”), 3 (“Al-
most always”) and 4 (“Always”) were filled. Persistence
was evaluated at 6-month periods (fixed for all the pa-
tients) and defined by an independent observer according
to the information recorded in standardized formats.
Ethics
The study was approved by the institution’s internal review
board (Comites de Ética e Investigación del Instituto Nacio-
nal de Ciencias Médicas y Nutrición Salvador Zubirán).
Written informed consent was obtained from all the pa-
tients when entering the clinic. Also, specific written con-
sent was obtained to have each patient’s charts reviewed
and data presented in scientific forums or publications.
Statistical analysis
Descriptive statistics, Student’s t test and χ2 test were used
as appropriate. Sociodemographic data are presented as
mean ± standard deviation (SD), and disease and treatmentcharacteristics are described as median and 25th–75th
interquartile range (IQR).
For each patient, persistence was evaluated at fixed
6-month intervals during the first 4 years of follow-up,
with a total of eight consecutive persistence evaluations
(persistence 1 to persistence 8); accordingly, for each pa-
tient, duration of persistence varied from 0 to 48 months.
Also, for each patient, the timing of (or follow-up to)
first non-persistence period was obtained and scored as
1 month (if first non-persistence was detected at persist-
ence 1 evaluation), 7 months (if first non-persistence
was detected at persistence 2 evaluation), 13 months (if
first non-persistence was detected at persistence 3 evalu-
ation), 19 months (if first non-persistence was detected
at persistence 4 evaluation) and successively (adding
6 months to each consecutive persistence evaluation) up
to 43 months if first non-persistence was detected at the
persistence 8 evaluation.
Linear regression analysis was used to investigate the im-
pact of the timing of the first non-persistence period and
the duration of persistence during the first 4 years of
follow-up (independent variables) on DAS28 and HAQ at
the fifth year of follow-up (dependent variables). Also, Cox
regression analysis was used to investigate whether the tim-
ing of the first non-persistence period and the duration of
persistence during the first 4 years of follow-up (independ-
ent variables) made a contribution to SR and sustained
function (SF) at the fifth year of follow-up (dependent vari-
ables). Variables included in the different models tested
were selected based on their statistical significance in the
univariate analysis and also on their clinical relevance (e.g.,
age and comorbidity). In particular, age was forced into the
models based on previous local report, where it has been
found a predictor of poor adherence and subsequently
worse outcomes [15]. Correlation between variables to be
included was also examined, and the final number of vari-
ables was limited by the number of outcomes of interest.
Significant variables were finally isolated using stepwise se-
lection. Analysis was repeated for each outcome and in the
subpopulation of female patients with RA.
All statistical tests were two-sided and evaluated at the
0.05 significance level. Statistical analysis was performed
using the IBM SPSS software program (v.17.0; IBM,
Armonk, NY, USA).
Results
Characteristics of the study population
Charts from 107 ERAPs were reviewed, and their data are
summarized in Table 1. Patients were predominantly fe-
male (88.8 %), middle-aged (mean ± SD was 39.1 ±
13.3 years), with 11.1 ± 3.9 years of formal education. Nine
patients (8.4 %) were current smokers when they entered
the clinic. At the baseline evaluation, 88 patients (82.2 %)
had rheumatoid factor (RF) and 92 (86 %) had anti-cyclic






SR (n = 39)
p Valuea
Sociodemographic variables
Female sex, n (%) 95 (88.8) 56 (82.4) 39 (100) 0.004
Age at baseline, years, (mean ± SD) 39.1 ± 13.3 38.6 ± 13.7 39.1 ± 13.4 0.85
Years of formal education, (mean ± SD) 11.1 ± 3.9 13.4 ± 4.1 8.6 ± 3 0.04
Current smokers, n (%) of patients 9 (8.4) 7 (10.3) 2 (22.2) 0.48
Disease characteristics at baselineb
Disease duration, months 5 (3.4–7) 4.2 (2.9–4.9) 4.9 (2.6–6.2) 0.22
Patients with RF, n (%) 88 (82.2) 54 (79.4) 34 (87.2) 0.43
Patients with ACCP, n (%) 92 (86) 57 (83.8) 35 (89.7) 0.57
DAS28 6 (5.1–7.1) 5.7 (4.6–6.7) 7 (6.1–7.8) 0.001
HAQ 1.5 (0.9–2.1) 1.3 (0.6–2) 1.9 (1.5–2.4) 0.000
Patients with erosions, n (%) 11 (10.3) 8 (11.8) 3 (7.7) 0.74
Number (%) of patients with ≥1 comorbidity 89 (77.4) 57 (83.8) 28 (71.8) 0.15
Number of comorbidities/patient 1 (1–2) 1 (1–2) 2 (1–2.8) 0.08
Cumulative treatment characteristicsb
Patients with corticosteroids, n (%) 58 (54.2) 33 (48.5) 25 (64.1) 0.16
Number of DMARDs/patient 2.2 (1.9–2.9) 2.2 (1.7–2.8) 2.6 (2–3) 0.03
Number (%) of patients with ≥1 non-persistence period 74 (69.2) 46 (67.6) 28 (71.8) 0.83
Follow-up at first non-persistence period,c mo 13 (1–31) 19 (7–31) 7 (1–23.5) 0.02
Persistence duration, mod 42 (30–48) 42 (30–48) 36(18–48) 0.07
ACCP Anti-cyclic citrullinated peptide antibodies, DAS28 Disease Activity Score in 28 joints, DMARD Disease-modifying anti-rheumatic drug, HAQ Health Assessment
Questionnaire, RF Rheumatoid factor, SD Standard deviation, SR Sustained remission
ap < 0.05 is statistically significant
bData are presented as median (25th–75th interquartile range) unless otherwise indicated
cRestricted to 74 patients with ≥1 non-persistence period
dIn the whole population
Table 2 Treatment strategies at baseline and last follow-up






Oral corticosteroids 42 (36.5) 48 (41.7)
Methotrexate monotherapy 20 (17.4) 43 (37.4)
2 combined DMARDs
(methotrexate required)
68 (59.1) 40 (34.8)
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ease (median [IQR] disease duration of 5 months [3.4–7]
and high disease activity [DAS28 of 6 [5.1–7.1]) and sub-
stantial disability (median [IQR] HAQ of 1.5 [0.9–2.1]).
Eleven patients (10.3 %) had erosive disease, and 89
(77.4 %) had at least one comorbid condition.
During the 4-year follow-up, 58 patients (54.2 %) had in-
dications for oral corticosteroids at some point, and all pa-
tients had indications for DMARDs. The median (IQR)
number of DMARDs per patient was 2.2 (1.9–2.9). Table 2
summarizes treatment at baseline and at last follow-up of
the evaluation of the persistence period. Also, 74 patients
(69.2 %) had at least one period of non-persistence, and
their follow-up to first non-persistence period was
13 months (1–31). Finally, the whole population had a
median (IQR) of 42 (30–48) months of persistence dur-
ing follow-up evaluated.≥3 combined DMARDs
(methotrexate required)
21 (18.3) 22 (19.1)
Other combinations of
traditional DMARDs
6 (5.2) 10 (8.7)
Biologic DMARDs 0 5 (4.3)
DMARDs disease-modifying anti-rheumatic drugsPredictors of disease activity and sustained remission
(sustained remission at the fifth year of follow-up)
During the fifth-year follow-up, 68 patients (63.6 %)
achieved SR and 39 (26.4 %) did not. Table 1 summarizesthese differences. Patients in the former group were less
frequently female, had more years of formal education,
had lower disease activity and disability at baseline, had in-
dications for fewer DMARDs per patient during follow-up
and tended to have a higher persistence duration and
more comorbidities per patient. Also, among the re-
stricted population with at least one non-persistence
period (n = 74), patients from the former group had longer
follow-up to first non-persistence period.
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follow-up, linear regression models were applied. The
following variables were entered in the model: sex, edu-
cation, baseline DAS28 (highly correlated to HAQ, ρ =
0.68, p ≤ 0.001), DMARDs per patient, timing of non-
persistence and persistence duration. In some models,
age and comorbidities per patient were forced. As shown
in Table 3, sex, baseline DAS28 and persistence duration
predicted DAS28 at the fifth year, and the strongest im-
pact was due to months of persistence. When the model
was tested in the subpopulation of women, DAS28 and
persistence duration were still the only predictors of dis-
ease activity at the fifth year (data not shown).
We then performed Cox regression analysis to deter-
mine predictors of achieving SR at the fifth year, and the
variables described above were considered in different
models tested. DAS28 at baseline (odds ratio [OR], 0.65;
95 % confidence interval [CI], 0.50–0.83; p ≤ 0.001), male
sex (OR, 0.42, 95 % CI, 0.18–0.97; p = 0.04) and persist-
ence duration within the first 4 years of follow-up (OR,
1.03, 95 % CI, 1–1.07; p = 0.06) were the only predictors
of SR at the fifth year. We repeated the analysis in the
female subpopulation. Comparison of women with ver-
sus without SR showed similar results to those described
in Table 1 (data not shown). In the Cox analysis, base-
line DAS28 (OR, 0.65; 95 % CI, 0.50–0.83; p = 0.001)
and persistence duration (OR, 1.04; 95 % CI, 1–1.08;
p = 0.05) still predictors.
In the subpopulation of women, according to receiver
operating characteristic curve analysis, the best cutoff
for persistence duration (during the first 4 years of
follow-up) to predict SR at the fifth year was 41.5 months
(sensitivity, 0.64; specificity, 0.64; area under the curve,
0.67; 95 % CI, 0.54–0.79) (Fig. 1).
Predictors of Health Assessment Questionnaire score and
sustained function at the fifth year of follow-up
During the fifth year of follow-up, 84 patients (78.5 %)
achieved SF according to our definition and 23 (21.5 %)Table 3 Linear regression models to predict DAS28 and HAQ
score at the fifth year of follow-up
Variablesa DAS28 at the fifth yearb HAQ at the fifth yearc
Male sex 0.64, (0.005 to 1.28), 0.05








Age 0.10, (0.004 to 0.016),
0.001
DAS28 Disease Activity Score in 28 joints, HAQ Health
Assessment Questionnaire
aData are presented as β coefficients (95 % confidence interval), p value
bR2 = 0.338
cR2 = 0.281did not. Table 4 summarizes differences between these
groups. Those who achieved SF were younger, tended to
be more educated, had more disease duration at diagno-
sis (although both had recent-onset disease), had lower
disease activity and disability at the baseline evaluation
and tended to have higher persistence duration.
To determine predictors of HAQ at fifth year, linear re-
gression models were applied. The following variables were
entered in the model: age, disease duration, baseline DAS28
(highly correlated to baseline HAQ; ρ= 0.68, p ≤ 0.001) and
persistence duration. Additional variables forced into the
model were treatment, timing of non-persistence and co-
morbidities per patient. As shown in Table 3, age and per-
sistence duration predicted HAQ at the fifth year. Similar
results were obtained when the model was applied to the
female subpopulation (data not shown).
We then performed Cox regression analysis to deter-
mine predictors of achieving SF at the fifth year, and the
variables described above were considered in different
models tested. DAS28 at baseline (OR, 0.79; 95 % CI,
0.66–0.94; p = 0.01) and age (OR, 0.97; 95 % CI, 0.95–
0.99; p = 0.002) were the only predictors of SR at the
fifth year.
Finally, all of the above analyses were repeated in the
population with at least one non-persistence period (n =
74), and similar results were obtained. Also, there was a
moderate correlation between duration of persistence
and follow-up to first non-persistence period (ρ = 0.46,
p ≤ 0.001). When persistence duration was switched in
models of follow-up to first non-persistence period, only
variables unrelated to the persistence construct prevailed.
Discussion
This study was developed in a well-characterized cohort of
Mexican Mestizo patients with early RA disease and sub-
stantial comorbidity. Standardized and complete follow-up
was performed by the same rheumatologist in a real clin-
ical setting. Follow-up included periodic and prospective
evaluations of comorbidity and of treatment persistence.
Conventional DMARDs given according to a T2T strategy
were the mainstay of treatment, and a substantial follow-
up was included. For all these reasons, we consider the
population described to be representative of “real-life pa-
tients”, so the results presented here have clinical and prac-
tical implications and can be generalized to populations
with similar characteristics.
The duration of persistence with DMARDs during the
first 4 years of follow-up was a predictor of disease activ-
ity at the consecutive year (in addition to baseline dis-
ease activity and sex) and of disability (in addition to
age). Also, persistence duration during the first 4 years
(along with lower baseline disease activity) predicted SR
at the consecutive year in women. The timing of first non-
persistence period (early vs. late) did not impact disease
Fig. 1 Receiver operating characteristic curve for cutoff for persistence duration to predict sustained remission. Curve plots the relationship
between sensitivity and specificity for the persistence duration cutoff to predict SR at the fifth year of follow-up
Table 4 Comparison of patients with versus without sustained function
Patients with SF at
fifth year, n = 84
Patients without SF at
fifth year, n = 23
p Valuea
Sociodemographic variables
Female sex, number (%) of patients 73 (86.9) 22 (95.7) 0.46
Age at baseline, yr (mean ± SD) 36.1 ± 12.2 48.5 ± 13.6 0.000
Years of formal education (mean ± SD) 11.3 ± 3.9 9.7 ± 4.2 0.09
Current smokers, number (%) of patients 9 (10.7) 0 (0) 0.2
Disease characteristics at baselineb
Disease duration, mo 5.3 (3.8–7.5) 3.8 (2.5–6.2) 0.05
Patients with RF, n (%) 69 (82.1) 19 (82.6) 1
Patients with ACCP, n (%) 72 (85.7) 20 (87) 1
DAS28 6 (4.9–6.9) 6.8 (6–7.7) 0.02
HAQ 1.4 (0.8–2) 2.1 (1.6–3) 0.000
Patients with erosions, n (%) 9 (10.7) 2 (8.7) 1
Number (%) of patients with ≥1 comorbidity 65 (77.4) 20 (87) 0.39
Number of comorbidities/patient 1 (1–2) 2 (1–2.8) 0.2
Cumulative treatment characteristicsb
Patients with corticosteroids, n (%) 42 (50) 16 (69.6) 0.11
Number of DMARDs/patient 2.3 (1.9-2.9) 2.4 (2–3) 0.44
Number (%) of patients with ≥1 non-persistence period 57 (76.9) 17 (73.9) 0.8
Follow-up at first non-persistence period,c mo 13 (1–31) 13 (1–22) 0.25
Persistence duration, mod 42 (30–48) 36 (12–48) 0.08
ACCP anti-cyclic citrullinated peptide antibodies, DAS28 Disease Activity Score in 28 joints, DMARDs disease-modifying anti-rheumatic drugs, HAQ Health
Assessment Questionnaire, RF rheumatoid factor, SD standard deviation, SF sustained function
ap < 0.05 is statistically significant
bData presented as median (25th–75th interquartile range) unless otherwise indicated
cRestricted to 74 patients with ≥1 non-persistence period
dIn the whole population
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4 years of follow-up that corresponded to 87.5 % of the
complete potential persistence length was the best cutoff
for persistence duration to predict SR in the subpopula-
tion of women, who were highly represented in our co-
hort. Finally, lower disease activity and younger age were
the only predictors of SF.
Our study confirms prior literature reviews which
highlighted that adherence to and persistence with trad-
itional and biologic DMARDs among patients with RA
are suboptimal [20–23]. Persistence impacted outcomes
in our population of early RA patients. Viller et al. also
showed better outcomes in European patients with early
RA (≤5-year disease duration) in whom compliance with
drug dosages and dosing times was assessed yearly using
a questionnaire [13]. We recently showed, in the same
inception cohort, better outcomes in adherent and per-
sistent patients in two different clinical scenarios: pa-
tients with high disease activity and disability and
patients in remission or who had low disease activity
[15, 16]. The present study adds additional information
to the field of the burden of inadequate therapeutic be-
havior in patients with RA patients. In addition to our
examination of sustained and major outcomes, we show
that the duration of persistence impacted disease out-
comes, whereas the timing of non-persistence did not.
Also, in the female subpopulation, a substantial persist-
ence duration with DMARDs was required to achieve
SR (almost 88 % of the entire length of persistence). Sev-
eral studies have shown that consistent adherence and
persistence among patients with chronic conditions drop
dramatically after the first 6 months of therapy [5, 24].
This may be particularly relevant in RA, where aggres-
sive treatment in the early phases of the disease has been
shown to prevent structural damage and to favor better
outcomes, including a higher remission rate [25–28]. In
such a clinical context, it may be intuitive to assume that
earlier non-persistence will affect favorable outcomes,
although non-persistence timing (early vs. late) did not
appear to be a predictor. Interestingly, persistence duration
was highly and negatively correlated with non-persistence
timing (Spearman’s ρ = −0.8, p ≤ 0.001), which may explain
the relevance of the former aspect of persistence over non-
persistence timing. Finally, the cutoff at least 87.5 % of per-
sistence duration to predict SR in the subpopulation of
women highlights the patient’s need to adhere closely to
prescriptions if major outcome benefits are desired. This
cutoff is higher than the arbitrary categories of good and
poor compliance, often set at 80 % [29], although that fig-
ure is based on a major and sustained outcome.
In addition to persistence duration, baseline DAS28,
age and sex impacted the outcomes of interest.
Lower disease activity at RA diagnosis was found to be
a predictor of subsequent disease activity, of SR and offunction. Combe et al. [30] also found that patients with
RA for whom therapy with one, two or three or more
DMARDs had failed and who had higher disease activity
at baseline were less likely to achieve remission after
6 months of golimumab. ten Kloster et al. [31] identified
baseline predictors of achieving satisfactory improvement
in pain in 209 ERAPs after 6 months of T2T therapy;
among the predictors was 12 or fewer tender joints at
baseline. Two additional studies performed in early RA
confirmed a lower initial number of tender joints (which
may be considered a surrogate of disease activity) as a pre-
dictor of remission [32, 33].
Age was found to be a predictor (in addition to disease
activity) of SF. Data from two large inception cohorts
identified that older age (in addition to other factors)
was associated with increased likelihood of membership
in subgroups with worse HAQ progression [34].
Young et al. [35] found that among 732 ERAPs, 9.4 %
had marked functional loss at 5 years of follow-up, and this
adverse functional outcome was more likely to occur in pa-
tients older than 60 years of age. Finally, the relationship
between disability and demographic and clinical variables
was analyzed in 684 patients with inflammatory polyarthri-
tis referred to the Norfolk Arthritis Register. Older age at
symptom onset (≥64 years) was one of the factors associ-
ated with disability as defined as HAQ of 1 or above [36].
Finally, female sex was an additional predictor of
unfavorable outcome, as previously reported in other pop-
ulations [37, 38]. Interestingly, women were highly repre-
sented in our cohort, as a female/male ratio of 7–8:1 has
been described in Latin American surveys, which is well
above the nearly 3:1 ratio reported in the United States
and Europe [39].
The present study has some limitations. The first is
that it is a single-center study, which potentially could
decrease the generalizability of the results. Second, per-
sistence was defined according to physician-reported
and patient-reported discontinuation of treatment, and
the threshold used to define non-persistence was arbi-
trarily chosen. Third, we analyzed the impact of a per-
sistence construct on outcomes, but we did not examine
the potential impact of a different construct such as ad-
herence (i.e., compliance with) to medication. Fourth, we
defined SF according as HAQ score of 20 or less. A dif-
ferent cutoff (0) on the HAQ-DI has been recommended
on the basis that it may be (more) intuitive and sensitive
and has face validity [40]. We repeated our analyses ac-
cording to such suggestions and obtained similar results.
Fifth, the study had a relatively short observation period
of 5 years. Sixth, we did not include local controls in
whom to assess the progression of functional disability
largely explained by the ageing process [41]. Seventh,
we did not include all the potential variables linked to
worse disability, such as body mass index [42]. Finally,
Contreras-Yáñez and Pascual-Ramos Arthritis Research & Therapy  (2015) 17:177 Page 8 of 9medication-taking behavior is a complex process in which
frequency, characteristics and predictors may vary over
the course of follow-up. Favorable and unfavorable disease
courses have both been associated with adherence to
therapy [12, 43], the latter reflecting, perhaps, the fact
that active patients regard complex therapy as useless.
Additional predictors are related to the disease itself,
the population enrolled and the indicated therapy. In
such a dynamic environment, the hypothetical causal
chain of outcomes–adherence–outcomes is debatable
and limits comprehensiveness of the topic.Conclusions
In the present study, we analyzed the impact of two par-
ticular aspects of the persistence construct—timing and
duration—on RA outcomes. Persistence duration during
the first 4 years of follow-up was a predictor of disease
activity and disability in the following year, whereas the
timing of non-persistence (earlier vs. late) was irrelevant.
We also confirmed in our population additional predic-
tors of favorable outcomes, such as younger age, male
sex and lower disease activity at diagnosis.
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